Sign in
Taking people in United StatesPhase 1/2

Tests two CAR T cell therapies together in young people with relapsed leukemia

Tests two modified immune cell treatments together in children and young adults with leukemia.

Key facts

Who runs it
Stephan Grupp MD PhD
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Co-administration of CART22-65s and huCART19 for B-ALL
Status
Recruiting
Phase
Phase 1/2
People taking part
93 people, planned
Started
25 Jan 2023
Expected to end
1 Jul 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults aged 0 to 29 years with B-cell acute lymphoblastic leukemia or lymphoma that came back, did not respond to treatment, or responded poorly to earlier B-cell cell therapy.

Age
0 to 29 years
Sex
All sexes can join.
Disease stage
B-cell ALL or B lineage lymphoblastic lymphoma with CD19 and/or CD22 on the cancer cells. Cohort A: relapsed or refractory disease. Cohort B: poor response to earlier B-cell directed engineered cell therapy. Past or current central nervous system disease is allowed if it responds to therapy.
Earlier treatment
Cohort B: poor response to earlier B-cell directed engineered cell therapy. Cannot need systemic steroids or immunosuppression at cell collection or infusion.
Biomarker or test result
CD19 and/or CD22 shown on the cancer cells by flow cytometry. After earlier CD19 or CD22 therapy, the test must be repeated after that therapy.

Main reasons for not taking part

  • Active hepatitis B or active hepatitis C
  • HIV infection
  • Graft versus host disease needing systemic therapy
  • Central nervous system disease that is getting worse on therapy
  • Pregnant or breastfeeding women, or an uncontrolled active infection

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Signed informed consent form
  • Patients with documented CD19+ and/or CD22+ ALL/LLy:; Cohort A: Patients with relapsed or refractory ALL/LLy:; Cohort B: Patients with poor response to prior B cell directed engineered cell therapy
  • Patients with prior or current history of Central Nervous System 3 disease will be eligible if Central Nervous System disease is responsive to therapy
  • Documentation of CD19 and/or CD22 tumor expression in bone marrow, peripheral blood, Cerebrospinal fluid, or tumor tissue by flow cytometry at the time of last detectable disease. If the patient has experienced a relapse after CD19-directed and/or CD22-directed therapy, flow cytometry should be evaluated after this therapy to demonstrate CD19 and/or CD22 expression
  • Age 0-29 years
  • Adequate organ function
  • Adequate performance status defined as Lanksy or Karnofsky performance score ≥50
  • Subjects of reproductive potential must agree to use acceptable birth control methods

Who cannot take part

  • Concurrent use of systemic steroids or immunosuppression at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well
  • Active hepatitis B or active hepatitis C
  • HIV infection
  • Active acute or chronic Graft Vs. Host Disease requiring systemic therapy
  • Central nervous system disease that is progressive on therapy, or with Central nervous system parenchymal lesions that might increase the risk of central nervous system toxicity
  • Uncontrolled active infection
  • Pregnant or nursing (lactating) women

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: CART Nurse NavigatorTaking people

About the trial

What the trial wants to find out

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

The 2 groups in the trial

  • Dose Finding ArmTreatment being tested

    Phase 1 will evaluate the safety of co-administration of CART22-65s with huCART19 in patients who experienced a disease relapse after prior CAR T cell therapy. There is no planned dose escalation but a dose-deescalation will be made based on the incidence of Dose Limiting Toxicities

    Treatment: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) and Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

  • Expansion ArmTreatment being tested

    If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) \& Cohort B (prior treatment with a prior CAR T cell product).

    Treatment: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) and Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL
Plain-language title
Tests two CAR T cell therapies together in young people with relapsed leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 March 2026